Smith & Nephew plc vs Vital Farms Inc — how do they compare? Smith & Nephew plc trades at $27.96 (market cap $11.62B), while Vital Farms Inc trades at $9.81 (market cap $424.16M). The key difference: Smith & Nephew plc is far larger — about 27.4× Vital Farms Inc's market cap, and Smith & Nephew plc pays a 2.86% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| SNN | VITL | |
|---|---|---|
Market Cap | $11.62B | $424.16M |
Sector | Health | Consumer Staples |
52-Week High | $38.53 | $48.56 |
52-Week Low | $27.80 | $8.28 |
Enterprise Value | $14.66B | $511.17M |
Dividend Yield | 2.86% | — |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $27.87, down 3.46% today and near a 52-week low. Technical indicators are bearish, but oversold RSI levels suggest potential for a rebound. Fundamentally, the company shows strong revenue growth to $6.16 billion in 2025 and a net income margin of 10.08%, though recent guidance cuts and CFO departure have weighed on sentiment. A dividend of $0.31 is scheduled for payment in November 2026.
The outlook is cautious due to competitive pressures and execution risks, but valuation metrics like a P/E of 18.96 appear reasonable. Analyst consensus is Hold, with 65% recommending neutrality. Upside depends on improved operational performance and stabilization in key markets.
Vital Farms (VITL) trades at $10.08, up 1.61% on the day, but faces bearish technical signals with key support at $9. The company reported a challenging Q2 2026 with a net loss per share of $0.47, though revenue of $166 million slightly beat expectations. Gross margin collapsed to 6.6% amid industry oversupply, but management reaffirmed full-year guidance and secured a $125 million term loan for stability.
The outlook is cautious; analyst consensus is a Buy with a $13.00 price target, but near-term risks include persistent margin pressure, cash burn, and competitive pricing gaps. Long-term recovery depends on execution against guidance and market stabilization.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →